{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:19:44Z","timestamp":1787685584808,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425002"],"award-info":[{"award-number":["82425002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270234"],"award-info":[{"award-number":["82270234"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82561160165"],"award-info":[{"award-number":["82561160165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82522004"],"award-info":[{"award-number":["82522004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270235"],"award-info":[{"award-number":["82270235"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370223"],"award-info":[{"award-number":["82370223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341206"],"award-info":[{"award-number":["82341206"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","award":["2023C03060"],"award-info":[{"award-number":["2023C03060"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","award":["2025C02075"],"award-info":[{"award-number":["2025C02075"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","award":["2024C03156"],"award-info":[{"award-number":["2024C03156"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41375-026-03017-x","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:42:31Z","timestamp":1783064551000},"page":"1927-1934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia"],"prefix":"10.1038","volume":"40","author":[{"given":"Mingming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0859-7281","authenticated-orcid":false,"given":"Dongrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-309X","authenticated-orcid":false,"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-1621","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-1852","authenticated-orcid":false,"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"3017_CR1","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026.","journal-title":"BMJ"},{"key":"3017_CR2","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/ajh.25162","volume":"93","author":"C Ganzel","year":"2018","unstructured":"Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. Am J Hematol. 2018;93:1074\u201381.","journal-title":"Am J Hematol"},{"key":"3017_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/cancers14030497","volume":"14","author":"J Marvin-Peek","year":"2022","unstructured":"Marvin-Peek J, Savani BN, Olalekan OO, Dholaria B. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia. Cancers (Basel). 2022;14:497.","journal-title":"Cancers (Basel)"},{"key":"3017_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15:88.","journal-title":"J Hematol Oncol"},{"key":"3017_CR5","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","volume":"36","author":"H Zhang","year":"2022","unstructured":"Zhang H, Bu C, Peng Z, Li G, Zhou Z, Ding W, et al. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia. 2022;36:2596\u2013604.","journal-title":"Leukemia"},{"key":"3017_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2023-179667","volume":"142","author":"NN Shah","year":"2023","unstructured":"Shah NN, Tasian SK, Kohler ME, Hsieh EM, Baumeister SHC, Summers C, et al. CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed\/Refractory AML: Dose-Escalation Results from a Phase I\/II Multicenter Trial. Blood. 2023;142:771.","journal-title":"Blood"},{"key":"3017_CR7","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia. 2021;35:3282\u20136.","journal-title":"Leukemia"},{"key":"3017_CR8","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/blood-2022-169928","volume":"140","author":"DA Sallman","year":"2022","unstructured":"Sallman DA, DeAngelo DJ, Pemmaraju N, Dinner S, Gill S, Olin RL, et al. Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R\/R) CD123+ Acute Myeloid Leukemia (AML). Blood. 2022;140:2371\u20133.","journal-title":"Blood"},{"key":"3017_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, et al. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma. Cancer Immunol Res. 2019;7:100\u201312.","journal-title":"Cancer Immunol Res"},{"key":"3017_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/(SICI)1096-8652(199808)58:4<278::AID-AJH5>3.0.CO;2-N","volume":"58","author":"A Saxena","year":"1998","unstructured":"Saxena A, Sheridan DP, Card RT, McPeek AM, Mewdell CC, Skinnider LF. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol. 1998;58:278\u201384.","journal-title":"Am J Hematol"},{"key":"3017_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, Perna F, K\u00f6hnke T, Schmidt C, Berman S, Augsberger C, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33:64\u201374.","journal-title":"Leukemia"},{"key":"3017_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/cyto.b.10028","volume":"53","author":"G Valet","year":"2003","unstructured":"Valet G, Repp R, Link H, Ehninger A, Gramatzki M M. SHG-AML study group. Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters. Cytometry B Clin Cytom. 2003;53:4\u201310.","journal-title":"Cytometry B Clin Cytom"},{"key":"3017_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/sj.leu.2401067","volume":"12","author":"A Venditti","year":"1998","unstructured":"Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox-Froncillo MC, Aronica G, et al. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia. 1998;12:1056\u201363.","journal-title":"Leukemia"},{"key":"3017_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cyto.b.20368","volume":"74","author":"J Zheng","year":"2008","unstructured":"Zheng J, Wang X, Hu Y, Yang J, Liu J, He Y, et al. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China. Cytometry B Clin Cytom. 2008;74:25\u20139.","journal-title":"Cytometry B Clin Cytom"},{"key":"3017_CR15","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1093\/intimm\/9.12.1875","volume":"9","author":"FA Bonilla","year":"1997","unstructured":"Bonilla FA, Kokron CM, Swinton P, Geha RS. Targeted gene disruption of murine CD7. Int Immunol. 1997;9:1875\u201383.","journal-title":"Int Immunol"},{"key":"3017_CR16","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.4049\/jimmunol.160.12.5749","volume":"160","author":"DM Lee","year":"1998","unstructured":"Lee DM, Staats HF, Sundy JS, Patel DD, Sempowski GD, Scearce RM, et al. Immunologic characterization of CD7-deficient mice. J Immunol. 1998;160:5749\u201356.","journal-title":"J Immunol"},{"key":"3017_CR17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32:995\u20131007.","journal-title":"Cell Res"},{"key":"3017_CR18","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140:321\u201334.","journal-title":"Blood"},{"key":"3017_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, et al. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis. N Engl J Med. 2024;390:1467\u201380.","journal-title":"N Engl J Med"},{"key":"3017_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3017_CR21","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54:1643\u201350.","journal-title":"Bone Marrow Transpl"},{"key":"3017_CR22","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Kerre T, Havelange V, Poir\u00e9 X, Lewalle P, Wang ES, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023;10:e191\u2013202.","journal-title":"Lancet Haematol"},{"key":"3017_CR23","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood.2024024861","volume":"145","author":"P Lu","year":"2025","unstructured":"Lu P, Zhang X, Yang J, Li J, Qiu L, Gong M, et al. Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia. Blood. 2025;145:1022\u201333.","journal-title":"Blood"},{"key":"3017_CR24","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, et al. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol. 2021;39:3340\u201351.","journal-title":"J Clin Oncol"},{"key":"3017_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215920","volume":"550","author":"X Si","year":"2022","unstructured":"Si X, Gu T, Liu L, Huang Y, Han Y, Qian P, et al. Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective. Cancer Letters. 2022;550:215920.","journal-title":"Cancer Letters"},{"key":"3017_CR26","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","volume":"28","author":"M Zhang","year":"2022","unstructured":"Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z, et al. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia\/Lymphoma. Clin Cancer Res. 2022;28:2830\u201343.","journal-title":"Clin Cancer Res"},{"key":"3017_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","volume":"16","author":"Y Tan","year":"2023","unstructured":"Tan Y, Shan L, Zhao L, Deng B, Ling Z, Zhang Y, et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2023;16:34.","journal-title":"J Hematol Oncol"},{"key":"3017_CR28","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504\u20136.","journal-title":"Nat Med"},{"key":"3017_CR29","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood.2025029299","volume":"146","author":"J Pan","year":"2025","unstructured":"Pan J, Zhao L, Zhang Y, Seery S, Tan Y, Deng B, et al. Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial. Blood. 2025;146:2745\u201357.","journal-title":"Blood"},{"key":"3017_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21168-6","volume":"12","author":"T Rabilloud","year":"2021","unstructured":"Rabilloud T, Potier D, Pankaew S, Nozais M, Loosveld M, Payet-Bornet D. Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nat Commun. 2021;12:865.","journal-title":"Nat Commun"},{"key":"3017_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13046-023-02841-8","volume":"42","author":"E Peroni","year":"2023","unstructured":"Peroni E, Randi ML, Rosato A, Cagnin S. Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment. J Exp Clin Cancer Res. 2023;42:259.","journal-title":"J Exp Clin Cancer Res"},{"key":"3017_CR32","doi-asserted-by":"publisher","unstructured":"Su L, Shi YY, Liu ZY, Gao SJ Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.806137.","DOI":"10.3389\/fonc.2022.806137"},{"key":"3017_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8722-3-15","volume":"3","author":"S R\u00f6hrs","year":"2010","unstructured":"R\u00f6hrs S, Scherr M, Romani J, Zaborski M, Drexler HG, Quentmeier H. CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation. J Hematol Oncol. 2010;3:15.","journal-title":"J Hematol Oncol"}],"updated-by":[{"DOI":"10.1038\/s41375-026-03091-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03017-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03017-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03017-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:02:45Z","timestamp":1787684565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03017-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3017"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03017-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The published article contained an error in the reporting of leukemia-free survival (LFS). In the Abstract and Efficacy sections, the 1-year LFS rate was incorrectly stated as 34.1% (95% CI: 4.7\u201363.5). This has been corrected to the actual 1-year LFS rate of 45.5% (95% CI: 16.1\u201374.9), which is consistent with the Kaplan-Meier curve presented in the article. In addition, the survival outcomes reported as \u201c1-year OS and LFS\u201d were incorrectly labeled. As the median follow-up of surviving patients was 3.11 years, these values represent 3-year OS and LFS rates, not 1-year rates. Therefore, all references to \u201c1-year OS and LFS\u201d in the Abstract and Efficacy sections have been corrected to \u201c3-year OS and LFS\u201d, while the reported values and corresponding confidence intervals remain unchanged. The corrected statements are as follows: Abstract: \u201cThe 3-year overall survival and leukemia-free survival rates were 34.3% and 34.1%, respectively\u201d. Efficacy section: \u201cThe 3-year OS and LFS rates were 34.3% (95% CI: 8.6-60.0) and 34.1% (95% CI: 4.7-63.5), respectively\u201d.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-026-03091-1","URL":"https:\/\/doi.org\/10.1038\/s41375-026-03091-1","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AHC is an employee of Shanghai YaKe Biotechnology. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}